FK-330 dihydrate

CAS No. 682813-92-9

FK-330 dihydrate( —— )

Catalog No. M36267 CAS No. 682813-92-9

FK-330 dihydrate (FR-260330 dihydrate) is a novel and effective nitric oxide synthase inhibitor. It can prevent ischemia and reperfusion injury in rat liver transplantation.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 553 In Stock
10MG 673 In Stock
25MG 901 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FK-330 dihydrate
  • Note
    Research use only, not for human use.
  • Brief Description
    FK-330 dihydrate (FR-260330 dihydrate) is a novel and effective nitric oxide synthase inhibitor. It can prevent ischemia and reperfusion injury in rat liver transplantation.
  • Description
    FK-330 dihydrate (FR-260330 dihydrate) is a novel and effective nitric oxide synthase inhibitor. It can prevent ischemia and reperfusion injury in rat liver transplantation.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Immunology/Inflammation
  • Target
    NOS
  • Recptor
    NO Synthase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    682813-92-9
  • Formula Weight
    653.05
  • Molecular Formula
    C29H32ClF3N6O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    O=C(N1CCC(CC1)OC2=NC=NC(C(F)(F)F)=C2)CNC([C@@H](NC(/C=C/C3=CC=C(C=C3)Cl)=O)CC4=CC=CC=N4)=O.O.O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Syringin

    Syringin has antitumour, antiproliferative, immunomodulatory and platelet aggregation inhibiting effects. Syringin can prevent Abeta(25-35)-induced neuronal cell damage.

  • Aminoguanidine hydro...

    Aminoguanidine hydrochloride is a diamine oxidase and NO synthase inhibitor.

  • Euscaphic acid

    Euscaphic acid has anti-diabetic, and anti-inflammatory activities, it inhibits LPS-induced inflammatory responses by interference with the clustering of TRAF6 with IRAK1 and TAK1, resulting in blocking the activation of IKK and MAPKs signal transduction to downregulate NF-κB activations.